Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

Inclusion Criteria: * Histological diagnosis of primary tumor as high-grade gliomas (WHO III or IV) * All patients should complete radiotherapy and chemotherapy for primary gliomas * Enhanced MRI and magnetic resonance spectroscopy showed unequivocal evidence of tumor recurrence or progression. * Those patients underwent surgical resection after tumor recurrence can also be enrolled if histological diagnosis of GBM is available, and MRI within 3 days after operation is needed. * The patients with recurrent gliomas didn't undergo bevacizumab therapy before enrollment. * The time to be enrolled should be more than 90 days after the radiation therapy, more than 28 days after operation for recurrent tumor or prior chemotherapy. * Eastern Cooperative Oncology Group score: 0-2 * Written informed consent * Laboratory test: Neutrophil count \> 1.5\*10\^9/L, platelet count \> 100\*109/L, hemoglobin \> 8 g/dL, blood urea nitrogen and creatinine \< 1.5 upper limit of normal(ULN), blood total bilirubin and conjugated bilirubin \< 1.5 ULN, alanine aminotransferase(ALT) and aspartate aminotransferase(AST) \< 3 ULN, alkaline phosphatase(AKP) \< 2 ULN Exclusion Criteria: * Pregnant or lactating women * Allergic to administered drugs * Radiation therapy in the previous 90 days before enrollment * The patients with recurrent gliomas were treated with bevacizumab therapy before enrollment. * Acute infection in need of antibiotics intravenously * Participation in other clinical trials in the 90 days before enrollment